Target intelligence / Profile preview

Ribosomal protein L21 pseudogene 104 (RPL21P104)

Target: RPL21P104
Molecular classification: Other (Pseudogene)

Overview

RPL21P104, or ribosomal protein L21 pseudogene 104, is a human genetic pseudogene corresponding to the ribosomal protein L21 but is not transcribed into a functional protein product[4][6]. Unlike its parent gene RPL21, which encodes a component of the 60S ribosomal subunit involved in protein synthesis[1][2], RPL21P104 is classified as a processed pseudogene, meaning it does not have therapeutic, biochemical, or disease-linked roles, nor does it encode a protein that could serve as a receptor, enzyme, or transporter[6]. It is not a valid drug target and is not relevant for biomarker or pharmacological considerations.

Other names: RPL21_45_1243RPL21P104

Beyond the preview

Go deeper on Ribosomal protein L21 pseudogene 104 (RPL21P104).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal protein L21 pseudogene 104 (RPL21P104).

Explore the full profile